August 2012
-
Evoke Pharma has announced that a Phase 3 trial of EVK-001 intranasal metoclopramide in 205 female diabetic gastroparesis patients failed to achieve its primary endpoint, which was improvement of symptoms at Week 4. EVK-001 and… Read more . . .
-
Pulmatrix has announced topline results from the Phase 1 bioavailability trial of Pulmatrix’s PUR0200 generic tiotropium DPI initiated in January 2016 and completed in May 2016. The company had previously announced positive Phase 1b results… Read more . . .
-
Windtree Therapeutics (formerly Discovery Laboratories) said that it has received an additional $1 million from a Phase 2 Small Business Innovation Research (SBIR) grant initially announced in October 2014. The grant, with a total potential… Read more . . .
-
The FDA has approved St. Renatus’s Kovanaze tetracaine HCl and oxymetazoline HCl nasal spray, the company announced. The product is approved for regional anesthesia for adults and children weighing 40 kg or more who are… Read more . . .
-
Inhaler component manufacturer H&T Presspart has announced the opening of a new sales office in Montevideo, Uruguay to serve customers in the South and Central American region. In addition, Jesus Polanco, formerly Business Development Manager… Read more . . .
-
While Health Canada conducts an expedited review of a new drug submission (NDS) for naloxone nasal spray, Minister of Health Jane Philpott has signed an Interim Order temporarily allowing naloxone nasal spray imported from the… Read more . . .
-
Therapix Biosciences has entered into an agreement with the Hebrew University’s technology transfer company Yissum to obtain an exclusive worldwide license for an intranasal formulation of cannabinoids developed by Elka Touitou of the university’s Institute… Read more . . .
-
UK-based formulation development company MedPharm has announced the opening of its new US subsidiary, MP Pharma Services, located in Durham, NC. MedPharm offers services for transdermal and topical, including inhaled and intranasal, formulations. MP Pharma… Read more . . .
-
Going into its 8th year, the annual Aerosol School at McMaster University in Hamilton, Ontario, Canada has added several new topics while continuing to provide a comprehensive basic education in aerosol medicines, says founder Myrna… Read more . . .
-
The FDA has made the approval packages for Boehringer Ingelheim’s Stiolto Respimat and Spiriva Respimat available on its website. The Stiolto Respimat tiotropium bromide/olodaterol SMI, which is marketed as Spiolto Respimat in Europe, was approved… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland